{"transactions":[{"id":4634952,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T22:49:12.000Z","date":"2026-09-22","kind":"exercise","planned":false,"acquired":false,"shares":756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":25.32,"expiration_date":"2026-09-22","underlying":"Common Stock","underlying_shares":756},"source":{"system":"sec-edgar","filing":"0001606302-26-000007","document":"wk-form4_1790966949.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000007/wk-form4_1790966949.xml","form_type":"4"}},{"id":4634951,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T22:49:12.000Z","date":"2026-09-22","kind":"exercise","planned":false,"acquired":true,"shares":756,"price":25.32,"value":19141.92,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029."}],"balance_after":1345063,"source":{"system":"sec-edgar","filing":"0001606302-26-000007","document":"wk-form4_1790966949.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000007/wk-form4_1790966949.xml","form_type":"4"}},{"id":713504,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-08T01:08:32.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":4200,"price":36.134,"value":151762.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse."}],"balance_after":84040,"source":{"system":"sec-edgar","filing":"0001543663-26-000017","document":"wk-form4_1783472909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000017/wk-form4_1783472909.xml","form_type":"4"}},{"id":713503,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-08T01:08:32.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":600,"price":36.021,"value":21612.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse."}],"balance_after":88240,"source":{"system":"sec-edgar","filing":"0001543663-26-000017","document":"wk-form4_1783472909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000017/wk-form4_1783472909.xml","form_type":"4"}},{"id":717686,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-02T22:42:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":1530,"price":35.227,"value":53897.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":88840,"source":{"system":"sec-edgar","filing":"0001543663-26-000015","document":"wk-form4_1783032175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000015/wk-form4_1783032175.xml","form_type":"4"}},{"id":717685,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-02T22:42:57.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":2531,"price":34.579,"value":87519.449,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":90370,"source":{"system":"sec-edgar","filing":"0001543663-26-000015","document":"wk-form4_1783032175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000015/wk-form4_1783032175.xml","form_type":"4"}},{"id":717684,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-07-02T22:42:57.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":739,"price":34.059,"value":25169.601,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":92901,"source":{"system":"sec-edgar","filing":"0001543663-26-000015","document":"wk-form4_1783032175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000015/wk-form4_1783032175.xml","form_type":"4"}},{"id":736018,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T21:32:10.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0001996804-26-000011","document":"wk-form4a_1781645528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199680426000011/wk-form4a_1781645528.xml","form_type":"4/A","original_submission_date":"2024-01-18"}},{"id":736017,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-16T21:32:05.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001996804-26-000010","document":"wk-form4a_1781645522.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199680426000010/wk-form4a_1781645522.xml","form_type":"4/A","original_submission_date":"2024-06-17"}},{"id":736016,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-06-16T21:31:59.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001996804-26-000009","document":"wk-form4a_1781645516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199680426000009/wk-form4a_1781645516.xml","form_type":"4/A","original_submission_date":"2025-06-13"}},{"id":786635,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-08T15:51:08.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":32.4358,"value":155691.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":93640,"source":{"system":"sec-edgar","filing":"0001543663-26-000013","document":"wk-form4_1778255465.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000013/wk-form4_1778255465.xml","form_type":"4"}},{"id":786634,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-05-08T15:51:08.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":30.0732,"value":144351.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":98440,"source":{"system":"sec-edgar","filing":"0001543663-26-000013","document":"wk-form4_1778255465.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000013/wk-form4_1778255465.xml","form_type":"4"}},{"id":788423,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":49091,"kind":"person","name":"Shafer Christina","position":1,"cik":"0001934412","reported_name":"Shafer Christina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-05-07T16:35:29.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":120000,"derivative":{"exercise_price":28.94,"expiration_date":"2036-05-05","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001934412-26-000006","document":"wk-form4_1778171726.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000193441226000006/wk-form4_1778171726.xml","form_type":"4"}},{"id":825182,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-30T21:38:27.000Z","date":"2026-03-26","kind":"sale","planned":true,"acquired":false,"shares":2558,"price":21.6247,"value":55315.9826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 26, 2026, a Restricted Stock Unit (\"RSU\") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":103240,"source":{"system":"sec-edgar","filing":"0001543663-26-000011","document":"wk-form4_1774905421.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000011/wk-form4_1774905421.xml","form_type":"4"}},{"id":825181,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-30T21:38:25.000Z","date":"2026-03-26","kind":"sale","planned":true,"acquired":false,"shares":3352,"price":22.0749,"value":73995.0648,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On March 26, 2026, a Restricted Stock Unit (\"RSU\") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"shares","element":"transactionShares","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029."}],"balance_after":1344307,"source":{"system":"sec-edgar","filing":"0001606302-26-000005","document":"wk-form4_1774905414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000005/wk-form4_1774905414.xml","form_type":"4"}},{"id":825180,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55302,"kind":"person","name":"Jordan Julie","position":1,"cik":"0001968554","reported_name":"Jordan Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-30T21:38:21.000Z","date":"2026-03-26","kind":"sale","planned":true,"acquired":false,"shares":828,"price":21.8932,"value":18127.5696,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On March 26, 2026, a Restricted Stock Unit (\"RSU\") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.68 to $22.19, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Consist of (a) 5,600 restricted stock units, which vest annually in equal installments on March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units which vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":12472,"source":{"system":"sec-edgar","filing":"0001968554-26-000005","document":"wk-form4_1774905406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000196855426000005/wk-form4_1774905406.xml","form_type":"4"}},{"id":837644,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:47.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":148,"price":22.08,"value":3267.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":30497,"source":{"system":"sec-edgar","filing":"0001994301-26-000004","document":"wk-form4_1773784904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199430126000004/wk-form4_1773784904.xml","form_type":"4"}},{"id":837643,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:47.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":2658,"price":21.34,"value":56721.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":30645,"source":{"system":"sec-edgar","filing":"0001994301-26-000004","document":"wk-form4_1773784904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199430126000004/wk-form4_1773784904.xml","form_type":"4"}},{"id":837642,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:47.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":3991,"price":20.41,"value":81456.31,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":33303,"source":{"system":"sec-edgar","filing":"0001994301-26-000004","document":"wk-form4_1773784904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199430126000004/wk-form4_1773784904.xml","form_type":"4"}},{"id":837641,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:02.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":263,"price":22.0195,"value":5791.1285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":105798,"source":{"system":"sec-edgar","filing":"0001543663-26-000007","document":"wk-form4_1773784859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000007/wk-form4_1773784859.xml","form_type":"4"}},{"id":837640,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:02.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":1395,"price":21.2451,"value":29636.9145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":106061,"source":{"system":"sec-edgar","filing":"0001543663-26-000007","document":"wk-form4_1773784859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000007/wk-form4_1773784859.xml","form_type":"4"}},{"id":837639,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-17T22:01:02.000Z","date":"2026-03-13","kind":"sale","planned":true,"acquired":false,"shares":2387,"price":20.4224,"value":48748.2688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":107456,"source":{"system":"sec-edgar","filing":"0001543663-26-000007","document":"wk-form4_1773784859.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000007/wk-form4_1773784859.xml","form_type":"4"}},{"id":866300,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-03-03T22:03:53.000Z","date":"2026-02-27","kind":"sale","planned":true,"acquired":false,"shares":4800,"price":25.1096,"value":120526.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":109843,"source":{"system":"sec-edgar","filing":"0001543663-26-000005","document":"wk-form4_1772575431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000005/wk-form4_1772575431.xml","form_type":"4"}},{"id":884493,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-24T23:49:39.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consist of (a) 13,594 restricted stock units remaining from a grant of 20,391 restricted stock units granted on March 13, 2024, which vests annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 7,200 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":37294,"source":{"system":"sec-edgar","filing":"0001994301-26-000002","document":"wk-form4_1771976976.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199430126000002/wk-form4_1771976976.xml","form_type":"4"}},{"id":884486,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55302,"kind":"person","name":"Jordan Julie","position":1,"cik":"0001968554","reported_name":"Jordan Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-24T23:49:24.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":29600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":29600,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":29600},"source":{"system":"sec-edgar","filing":"0001968554-26-000002","document":"wk-form4_1771976961.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000196855426000002/wk-form4_1771976961.xml","form_type":"4"}},{"id":884485,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55302,"kind":"person","name":"Jordan Julie","position":1,"cik":"0001968554","reported_name":"Jordan Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-24T23:49:24.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":4900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":13300,"source":{"system":"sec-edgar","filing":"0001968554-26-000002","document":"wk-form4_1771976961.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000196855426000002/wk-form4_1771976961.xml","form_type":"4"}},{"id":884488,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-24T23:49:01.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":131900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":131900,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":131900},"source":{"system":"sec-edgar","filing":"0001543663-26-000002","document":"wk-form4_1771976938.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000002/wk-form4_1771976938.xml","form_type":"4"}},{"id":884487,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2026-02-24T23:49:01.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.  Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":114643,"source":{"system":"sec-edgar","filing":"0001543663-26-000002","document":"wk-form4_1771976938.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000154366326000002/wk-form4_1771976938.xml","form_type":"4"}},{"id":884484,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-24T23:48:26.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":155100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":155100,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":155100},"source":{"system":"sec-edgar","filing":"0001606302-26-000002","document":"wk-form4_1771976903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000002/wk-form4_1771976903.xml","form_type":"4"}},{"id":884483,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-24T23:48:26.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":25900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.  Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024.  This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person."}],"balance_after":1347659,"source":{"system":"sec-edgar","filing":"0001606302-26-000002","document":"wk-form4_1771976903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000160630226000002/wk-form4_1771976903.xml","form_type":"4"}},{"id":884482,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T23:41:39.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001274826-26-000002","document":"wk-form4_1771976497.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000127482626000002/wk-form4_1771976497.xml","form_type":"4"}},{"id":884481,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64919,"kind":"person","name":"Freedland Cory S.","position":1,"cik":"0001832569","reported_name":"Freedland Cory S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T23:40:27.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001832569-26-000002","document":"wk-form4_1771976424.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000183256926000002/wk-form4_1771976424.xml","form_type":"4"}},{"id":884480,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":37647,"kind":"person","name":"Woods Keith","position":1,"cik":"0001996804","reported_name":"Woods Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T23:40:02.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001996804-26-000002","document":"wk-form4_1771976400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000199680426000002/wk-form4_1771976400.xml","form_type":"4"}},{"id":884526,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64921,"kind":"person","name":"PALEKAR ROHAN","position":1,"cik":"0001423327","reported_name":"PALEKAR ROHAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T18:48:05.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001628280-26-011325","document":"wk-form4_1771976881.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423327/000162828026011325/wk-form4_1771976881.xml","form_type":"4"}},{"id":885009,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2026-02-24T18:40:45.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-20","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001706301-26-000002","document":"wk-form4_1771976443.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000170630126000002/wk-form4_1771976443.xml","form_type":"4"}},{"id":1111414,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T16:07:42.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000068","document":"wk-form4_1749830856.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000068/wk-form4_1749830856.xml","form_type":"4"}},{"id":1111412,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":78505,"kind":"person","name":"Woods Robert Keith","position":1,"cik":"0001995131","reported_name":"Woods Robert Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T16:07:13.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000067","document":"wk-form4_1749830826.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000067/wk-form4_1749830826.xml","form_type":"4"}},{"id":1111413,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64919,"kind":"person","name":"Freedland Cory S.","position":1,"cik":"0001832569","reported_name":"Freedland Cory S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T16:06:17.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000065","document":"wk-form4_1749830770.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000065/wk-form4_1749830770.xml","form_type":"4"}},{"id":1111423,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64921,"kind":"person","name":"PALEKAR ROHAN","position":1,"cik":"0001423327","reported_name":"PALEKAR ROHAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T12:06:44.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000066","document":"wk-form4_1749830797.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423327/000140464425000066/wk-form4_1749830797.xml","form_type":"4"}},{"id":1111733,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2025-06-13T12:05:49.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":12050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12050,"derivative":{"exercise_price":20.4,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":12050},"source":{"system":"sec-edgar","filing":"0001404644-25-000064","document":"wk-form4_1749830742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000140464425000064/wk-form4_1749830742.xml","form_type":"4"}},{"id":1147228,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-05-15T20:43:07.000Z","date":"2025-05-14","kind":"sale","planned":true,"acquired":false,"shares":6797,"price":15.1542,"value":103003.0974,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.75. The reporting person undertakes to provide Neurogene Inc. (the \"Company\"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20794,"source":{"system":"sec-edgar","filing":"0001404644-25-000046","document":"wk-form4_1747341779.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000046/wk-form4_1747341779.xml","form_type":"4"}},{"id":1188769,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2025-03-29T01:30:38.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":42900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 42,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal month installments through the fourth anniversary of the grant date."}],"balance_after":42900,"derivative":{"exercise_price":16.14,"expiration_date":"2035-03-26","underlying":"Common Stock","underlying_shares":42900},"source":{"system":"sec-edgar","filing":"0001404644-25-000025","document":"wk-form4_1743211830.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000025/wk-form4_1743211830.xml","form_type":"4"}},{"id":1188768,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-29T01:30:38.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":7200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of 7,200 restricted stock units, which will vest in three equal annual installments beginning with the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":27591,"source":{"system":"sec-edgar","filing":"0001404644-25-000025","document":"wk-form4_1743211830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000025/wk-form4_1743211830.xml","form_type":"4"}},{"id":1188765,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2025-03-29T01:29:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":122000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents the right to purchase 122,000 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the date of grant with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":122000,"derivative":{"exercise_price":16.14,"expiration_date":"2035-03-26","underlying":"Common Stock","underlying_shares":122000},"source":{"system":"sec-edgar","filing":"0001404644-25-000023","document":"wk-form4_1743211773.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000023/wk-form4_1743211773.xml","form_type":"4"}},{"id":1188764,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2025-03-29T01:29:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":20300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 20,300 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":92643,"source":{"system":"sec-edgar","filing":"0001404644-25-000023","document":"wk-form4_1743211773.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000023/wk-form4_1743211773.xml","form_type":"4"}},{"id":1188763,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55302,"kind":"person","name":"Jordan Julie","position":1,"cik":"0001968554","reported_name":"Jordan Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2025-03-29T01:28:27.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":50300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 50,300 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":50300,"derivative":{"exercise_price":16.14,"expiration_date":"2035-03-26","underlying":"Common Stock","underlying_shares":50300},"source":{"system":"sec-edgar","filing":"0001404644-25-000021","document":"wk-form4_1743211701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000021/wk-form4_1743211701.xml","form_type":"4"}},{"id":1188762,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55302,"kind":"person","name":"Jordan Julie","position":1,"cik":"0001968554","reported_name":"Jordan Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-29T01:28:27.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 8,400 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":8400,"source":{"system":"sec-edgar","filing":"0001404644-25-000021","document":"wk-form4_1743211701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000021/wk-form4_1743211701.xml","form_type":"4"}},{"id":1188761,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2025-03-29T01:27:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":143500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":143500,"derivative":{"exercise_price":16.14,"exercise_date":"2025-03-26","underlying":"Common Stock","underlying_shares":143500},"source":{"system":"sec-edgar","filing":"0001404644-25-000020","document":"wk-form4_1743211653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000020/wk-form4_1743211653.xml","form_type":"4"}},{"id":1188760,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-29T01:27:40.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":23900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date."}],"balance_after":1274259,"source":{"system":"sec-edgar","filing":"0001404644-25-000020","document":"wk-form4_1743211653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000020/wk-form4_1743211653.xml","form_type":"4"}},{"id":1203615,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2025-03-17T21:14:56.000Z","date":"2025-03-13","kind":"sale","planned":true,"acquired":false,"shares":4501,"price":16.94,"value":76246.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 12, 2024, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part.  The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person.  The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person.  The sale reported on this Form 4 relates exclusively to this mandatory sale upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.38 to $17.21, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":72343,"source":{"system":"sec-edgar","filing":"0001404644-25-000007","document":"wk-form4_1742246088.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464425000007/wk-form4_1742246088.xml","form_type":"4"}},{"id":1349176,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":1,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":3,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:39:29.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":27.5,"value":55000.0,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by Samsara BioCapital L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1717127,"source":{"system":"sec-edgar","filing":"0001415889-24-027861","document":"form4-11272024_091125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000141588924027861/form4-11272024_091125.xml","form_type":"4"}},{"id":1349175,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":1,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":3,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:39:29.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":15219,"price":26.73,"value":406803.87,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by Samsara BioCapital L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1715127,"source":{"system":"sec-edgar","filing":"0001415889-24-027861","document":"form4-11272024_091125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000141588924027861/form4-11272024_091125.xml","form_type":"4"}},{"id":1349174,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":1,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":3,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:39:29.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":10803,"price":26.01,"value":280986.03,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.47 to $26.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by Samsara BioCapital L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1699908,"source":{"system":"sec-edgar","filing":"0001415889-24-027861","document":"form4-11272024_091125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000141588924027861/form4-11272024_091125.xml","form_type":"4"}},{"id":1349173,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":44747,"kind":"organization","name":"Samsara BioCapital GP, LLC","position":1,"cik":"0001888829","reported_name":"Samsara BioCapital GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":44746,"kind":"organization","name":"Samsara BioCapital, L.P.","position":2,"cik":"0001699737","reported_name":"Samsara BioCapital, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":32933,"kind":"person","name":"AKKARAJU SRINIVAS","position":3,"cik":"0001253170","reported_name":"AKKARAJU SRINIVAS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T21:39:29.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":20748,"price":24.91,"value":516832.68,"ownership":{"direct":false,"nature":"By Samsara BioCapital, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.25 to $25.23 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by Samsara BioCapital L.P. (\"Samsara LP\"). Samsara BioCapital GP, LLC (\"Samsara LLC\") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1689105,"source":{"system":"sec-edgar","filing":"0001415889-24-027861","document":"form4-11272024_091125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000141588924027861/form4-11272024_091125.xml","form_type":"4"}},{"id":1352551,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2024-11-26T02:29:29.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":24000,"price":20.475,"value":491400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.33 to $20.92, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic."}],"balance_after":76844,"source":{"system":"sec-edgar","filing":"0001404644-24-000113","document":"wk-form4_1732588163.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000113/wk-form4_1732588163.xml","form_type":"4"}},{"id":1352550,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-11-26T02:29:04.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":47500,"price":20.4,"value":969000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.07 to $20.84, inclusive. The reporting person undertakes to provide to Neurogene Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":1297859,"source":{"system":"sec-edgar","filing":"0001404644-24-000112","document":"wk-form4_1732588138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000112/wk-form4_1732588138.xml","form_type":"4"}},{"id":1477157,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":78505,"kind":"person","name":"Woods Robert Keith","position":1,"cik":"0001995131","reported_name":"Woods Robert Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T18:37:33.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000071","document":"wk-form4_1718649445.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000071/wk-form4_1718649445.xml","form_type":"4"}},{"id":1477158,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T18:36:28.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000069","document":"wk-form4_1718649381.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000069/wk-form4_1718649381.xml","form_type":"4"}},{"id":1477156,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64919,"kind":"person","name":"Freedland Cory S.","position":1,"cik":"0001832569","reported_name":"Freedland Cory S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T18:35:37.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000067","document":"wk-form4_1718649330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000067/wk-form4_1718649330.xml","form_type":"4"}},{"id":1477170,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64921,"kind":"person","name":"PALEKAR ROHAN","position":1,"cik":"0001423327","reported_name":"PALEKAR ROHAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T14:37:01.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000070","document":"wk-form4_1718649414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423327/000140464424000070/wk-form4_1718649414.xml","form_type":"4"}},{"id":1477340,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T14:36:03.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":7700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date."}],"balance_after":7700,"derivative":{"exercise_price":42.59,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":7700},"source":{"system":"sec-edgar","filing":"0001404644-24-000068","document":"wk-form4_1718649355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000140464424000068/wk-form4_1718649355.xml","form_type":"4"}},{"id":1576492,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55303,"kind":"person","name":"McMinn Rachel","position":1,"cik":"0001606302","reported_name":"McMinn Rachel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2024-03-15T00:54:55.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":93282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":93282,"derivative":{"exercise_price":36.06,"expiration_date":"2034-03-13","underlying":"Common Stock","underlying_shares":93282},"source":{"system":"sec-edgar","filing":"0001404644-24-000010","document":"wk-form4_1710464082.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000010/wk-form4_1710464082.xml","form_type":"4"}},{"id":1576491,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2024-03-15T00:53:21.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":53900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":53900,"derivative":{"exercise_price":36.06,"expiration_date":"2034-03-13","underlying":"Common Stock","underlying_shares":53900},"source":{"system":"sec-edgar","filing":"0001404644-24-000008","document":"wk-form4_1710463991.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000008/wk-form4_1710463991.xml","form_type":"4"}},{"id":1576490,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":31665,"kind":"person","name":"Cvijic Christine Mikail","position":1,"cik":"0001543663","reported_name":"Cvijic Christine Mikail","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CFO"}}],"security":"Common Stock","published_at":"2024-03-15T00:53:21.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":31903,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52844,"source":{"system":"sec-edgar","filing":"0001404644-24-000008","document":"wk-form4_1710463991.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000008/wk-form4_1710463991.xml","form_type":"4"}},{"id":1576489,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-15T00:51:43.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":34450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date."}],"balance_after":34450,"derivative":{"exercise_price":36.06,"expiration_date":"2034-03-13","underlying":"Common Stock","underlying_shares":34450},"source":{"system":"sec-edgar","filing":"0001404644-24-000006","document":"wk-form4_1710463892.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000006/wk-form4_1710463892.xml","form_type":"4"}},{"id":1576488,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":59934,"kind":"person","name":"Cobb Stuart","position":1,"cik":"0001994301","reported_name":"Cobb Stuart","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-15T00:51:43.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":20391,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20391,"source":{"system":"sec-edgar","filing":"0001404644-24-000006","document":"wk-form4_1710463892.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000006/wk-form4_1710463892.xml","form_type":"4"}},{"id":1676218,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":78505,"kind":"person","name":"Woods Robert Keith","position":1,"cik":"0001995131","reported_name":"Woods Robert Keith","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T00:01:01.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005541","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000095017024005541/ownership.xml","form_type":"4"}},{"id":1676217,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64919,"kind":"person","name":"Freedland Cory S.","position":1,"cik":"0001832569","reported_name":"Freedland Cory S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T23:53:15.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005535","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000095017024005535/ownership.xml","form_type":"4"}},{"id":1676216,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64920,"kind":"person","name":"BAFFI ROBERT","position":1,"cik":"0001274826","reported_name":"BAFFI ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T23:51:00.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005533","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000095017024005533/ownership.xml","form_type":"4"}},{"id":1676215,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":55302,"kind":"person","name":"Jordan Julie","position":1,"cik":"0001968554","reported_name":"Jordan Julie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T23:48:20.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 75,000 shares of common stock of the Issuer, of which 25% vests on the first anniversary of the grant date and the remainder vests in equal monthly installments through January 16, 2028, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":75000,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-005531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404644/000095017024005531/ownership.xml","form_type":"4"}},{"id":1676254,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64921,"kind":"person","name":"PALEKAR ROHAN","position":1,"cik":"0001423327","reported_name":"PALEKAR ROHAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T18:58:27.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1423327/000095017024005539/ownership.xml","form_type":"4"}},{"id":1676435,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":64953,"kind":"person","name":"Noonberg Sarah B.","position":1,"cik":"0001706301","reported_name":"Noonberg Sarah B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-18T18:56:12.000Z","date":"2024-01-16","kind":"grant","planned":false,"acquired":true,"shares":15400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date."}],"balance_after":15400,"derivative":{"exercise_price":32.3,"expiration_date":"2034-01-16","underlying":"Common Stock","underlying_shares":15400},"source":{"system":"sec-edgar","filing":"0000950170-24-005537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706301/000095017024005537/ownership.xml","form_type":"4"}},{"id":1703667,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":1151124,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"As a result of and upon the effective time of the Merger, the Funds acquired $0.000001 Prefunded Warrants in exchange for existing shares of Neurogene Series B Preferred Stock (\"Series B Preferred\") at a rate of 0.0756 $0.000001 Prefunded Warrants for each share of Series B Preferred."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P.\nand (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."}],"balance_after":2656101,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1151124},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703666,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":93480,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"As a result of and upon the effective time of the Merger, the Funds acquired $0.000001 Prefunded Warrants in exchange for existing shares of Neurogene Series B Preferred Stock (\"Series B Preferred\") at a rate of 0.0756 $0.000001 Prefunded Warrants for each share of Series B Preferred."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":221149,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":93480},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703665,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":221557,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"As a result of and upon the effective time of the Merger, the Funds acquired $0.000001 Prefunded Warrants in exchange for existing shares of Neurogene Series A-2 Preferred Stock (\"Series A-2 Preferred\") at a rate of 0.0756 $0.000001 Prefunded Warrants for each share of Series A-2 Preferred."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P.\nand (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":1504977,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":221557},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703664,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":20562,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"As a result of and upon the effective time of the Merger, the Funds acquired $0.000001 Prefunded Warrants in exchange for existing shares of Neurogene Series A-2 Preferred Stock (\"Series A-2 Preferred\") at a rate of 0.0756 $0.000001 Prefunded Warrants for each share of Series A-2 Preferred."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":127669,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":20562},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703663,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":310130,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"As a result of and upon the effective time of the Merger, the Funds acquired $0.000001 Prefunded Warrants in exchange for existing shares of Neurogene Series A-1 Preferred Stock (\"Series A-1 Preferred\") at a rate of 0.0756 $0.000001 Prefunded Warrants for each share of Series A-1 Preferred."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P.\nand (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":1283420,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":310130},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703662,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":28782,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"As a result of and upon the effective time of the Merger, the Funds acquired $0.000001 Prefunded Warrants in exchange for existing shares of Neurogene Series A-1 Preferred Stock (\"Series A-1 Preferred\") at a rate of 0.0756 $0.000001 Prefunded Warrants for each share of Series A-1 Preferred."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":107107,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":28782},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703661,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":973290,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"667 and Life Sciences acquired 78,325 and 973,290 warrants to purchase Common Stock, respectively, at an exercise price of $0.000001 per share (\"$0.000001 Prefunded Warrants\") in the Merger at a rate of 0.0756 $0.000001 Prefunded\nWarrants for each Neurogen Prefunded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P.\nand (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."}],"balance_after":973290,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":973290},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1703660,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":3,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":4,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":5,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":6,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Prefunded Warrants","published_at":"2023-12-20T23:43:06.000Z","date":"2023-12-18","kind":"grant","planned":false,"acquired":true,"shares":78325,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"667 and Life Sciences acquired 78,325 and 973,290 warrants to purchase Common Stock, respectively, at an exercise price of $0.000001 per share (\"$0.000001 Prefunded Warrants\") in the Merger at a rate of 0.0756 $0.000001 Prefunded\nWarrants for each Neurogen Prefunded Warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 18, 2023 (the \"Closing Date\"), Neurogene Inc., a Delaware corporation (formerly known as Neoleukin Therapeutics, Inc. (prior to the Closing Date, \"Neoleukin\", and after the Closing Date, the \"Issuer\")) consummated the previously announced business combination (the \"Merger\") pursuant to that certain Agreement and Plan of Merger, dated as of July 17, 2023 (the \"Merger Agreement\"), by and among Neoleukin, Project North Merger Sub, Inc., a wholly owned subsidiary of Neoleukin (\"Merger Sub\"), and Neurogene Inc., a Nevada corporation (\"Neurogene\"). At the closing of the Merger Neoleukin Therapeutics, Inc. changed its name to Neurogene Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except\nto the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the\nAdviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"By written notice to the Issuer, the Funds may increase or decrease the Maximum Percentage applicable to that fund to any other percentage not in excess of 19.99%; provided that any such increase will not be effective until the 61st day after such notice is delivered to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The $0.000001 Prefunded Warrants are exercisable at any time, at the holder's election, on a 1-for-1 basis into Common Stock to the extent that immediately prior to or after giving effect to such exercise the holders and/ or their affiliates thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than the Maximum Percentage. The Prefunded Warrants have no expiration date."}],"balance_after":78325,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":78325},"source":{"system":"sec-edgar","filing":"0001209191-23-059388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123059388/doc4.xml","form_type":"4"}},{"id":1762898,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants","published_at":"2023-10-10T20:22:19.000Z","date":"2023-10-05","kind":"other","planned":false,"acquired":false,"shares":535601,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to Instruction 4(c)(iii), this response has been left blank."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-5 reverse stock split of the Common Stock effected by the Issuer on September 25, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects a 1-for-5 reverse stock split of the Common Stock effected by the Issuer on September 25, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":1521176,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":535601},"source":{"system":"sec-edgar","filing":"0001209191-23-052526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123052526/doc4.xml","form_type":"4"}},{"id":1762897,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrants","published_at":"2023-10-10T20:22:19.000Z","date":"2023-10-05","kind":"other","planned":false,"acquired":false,"shares":57049,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to Instruction 4(c)(iii), this response has been left blank."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-5 reverse stock split of the Common Stock effected by the Issuer on September 25, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects a 1-for-5 reverse stock split of the Common Stock effected by the Issuer on September 25, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in securities reported in column 9 of Table II\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."}],"balance_after":182775,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":57049},"source":{"system":"sec-edgar","filing":"0001209191-23-052526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123052526/doc4.xml","form_type":"4"}},{"id":1762896,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-10T20:22:19.000Z","date":"2023-10-05","kind":"other","planned":false,"acquired":true,"shares":535601,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects a 1-for-5 reverse stock split of the Common Stock effected by the Issuer on September 25, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":1658190,"source":{"system":"sec-edgar","filing":"0001209191-23-052526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123052526/doc4.xml","form_type":"4"}},{"id":1762895,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-10T20:22:19.000Z","date":"2023-10-05","kind":"other","planned":false,"acquired":true,"shares":57049,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects a 1-for-5 reverse stock split of the Common Stock effected by the Issuer on September 25, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"On October 5, 2023, 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") exercised prefunded warrants with an exercise price of $0.000005 per share (\"Prefunded Warrants\") to purchase 57,049 and 535,601 shares, respectively. The Prefunded Warrants have no expiration date and are exercisable immediately on a 1-for-1 basis into Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."}],"balance_after":155874,"source":{"system":"sec-edgar","filing":"0001209191-23-052526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123052526/doc4.xml","form_type":"4"}},{"id":1804336,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":61134,"price":0.6928,"value":42353.6352,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6800 to $0.7065, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5612949,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804335,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":5041,"price":0.6928,"value":3492.4048,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6800 to $0.7065, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":494133,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804334,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":93091,"price":0.6924,"value":64456.2084,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6899 to $0.7100, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5551815,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804333,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-17","kind":"purchase","planned":false,"acquired":true,"shares":7676,"price":0.6924,"value":5314.8624,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6899 to $0.7100, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":489092,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804332,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":4434,"price":0.6828,"value":3027.5352,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5458724,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804331,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":366,"price":0.6828,"value":249.9048,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":481416,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804330,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":207676,"price":0.6805,"value":141323.518,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6701 to $0.6991, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5454290,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804329,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-16","kind":"purchase","planned":false,"acquired":true,"shares":17124,"price":0.6805,"value":11652.882,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $0.6701 to $0.6991, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":481050,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804328,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-15","kind":"purchase","planned":false,"acquired":true,"shares":4342,"price":0.665,"value":2887.43,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5246614,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804327,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-15","kind":"purchase","planned":false,"acquired":true,"shares":358,"price":0.665,"value":238.07,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":463926,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804326,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-15","kind":"purchase","planned":false,"acquired":true,"shares":1740581,"price":0.6308,"value":1097958.4948,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $0.615 to $0.68, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":5242272,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1804325,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-17T21:08:02.000Z","date":"2023-08-15","kind":"purchase","planned":false,"acquired":true,"shares":143519,"price":0.6308,"value":90531.7852,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $0.615 to $0.68, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667,\nJulian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I\ndirectly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole\ngeneral partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of\na portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":463568,"source":{"system":"sec-edgar","filing":"0001209191-23-046351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123046351/doc4.xml","form_type":"4"}},{"id":1808779,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":110573,"kind":"person","name":"Smith Sean Michael","position":1,"cik":"0001914769","reported_name":"Smith Sean Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO, Prin Acct Off"}}],"security":"Restricted Stock Units","published_at":"2023-08-14T16:06:55.000Z","date":"2023-08-10","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of August 10, 2022 and August 10, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-23-045611","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1914769/000120919123045611/doc4.xml","form_type":"4"}},{"id":1808778,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":110573,"kind":"person","name":"Smith Sean Michael","position":1,"cik":"0001914769","reported_name":"Smith Sean Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO, Prin Acct Off"}}],"security":"Common Stock","published_at":"2023-08-14T16:06:55.000Z","date":"2023-08-11","kind":"sale","planned":false,"acquired":false,"shares":1323,"price":0.6184,"value":818.1432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $.6146 and the highest price at which shares were sold was $0.6399. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,000 shares of common stock acquired by the Reporting Person on May 15, 2023 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":21637,"source":{"system":"sec-edgar","filing":"0001209191-23-045611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1914769/000120919123045611/doc4.xml","form_type":"4"}},{"id":1808777,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":110573,"kind":"person","name":"Smith Sean Michael","position":1,"cik":"0001914769","reported_name":"Smith Sean Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO, Prin Acct Off"}}],"security":"Common Stock","published_at":"2023-08-14T16:06:55.000Z","date":"2023-08-10","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,000 shares of common stock acquired by the Reporting Person on May 15, 2023 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":22960,"source":{"system":"sec-edgar","filing":"0001209191-23-045611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1914769/000120919123045611/doc4.xml","form_type":"4"}},{"id":1859442,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":3,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":4,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":5,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":6,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-06-12T20:03:22.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 25,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Neoleukin Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 8, 2023, in her capacity as director of the Issuer, pursuant to the Issuer's 2014 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.79 and vest in 12 equal monthly installments beginning on July 8, 2023, subject to M. Cantey Boyd's continued service on the board of directors of the Issuer (the \"Board\") and expire on June 7, 2033. M. Cantey Boyd serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 25,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Neoleukin Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 8, 2023, in her capacity as director of the Issuer, pursuant to the Issuer's 2014 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.79 and vest in 12 equal monthly installments beginning on July 8, 2023, subject to M. Cantey Boyd's continued service on the board of directors of the Issuer (the \"Board\") and expire on June 7, 2033. M. Cantey Boyd serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Includes 25,000 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Neoleukin Therapeutics, Inc. (the \"Issuer\") granted by the Issuer to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the \"Adviser\") on June 8, 2023, in her capacity as director of the Issuer, pursuant to the Issuer's 2014 Equity Incentive Plan (the \"Incentive Plan\"). The Stock Options have a strike price of $0.79 and vest in 12 equal monthly installments beginning on July 8, 2023, subject to M. Cantey Boyd's continued service on the board of directors of the Issuer (the \"Board\") and expire on June 7, 2033. M. Cantey Boyd serves on the Board as a representative of Baker Brothers Life Sciences, L.P. (\"Life Sciences\") and 667, L.P. (\"667\", and together with Life Sciences, the \"Funds\") and their affiliates."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to the policies of the Adviser, M. Cantey Boyd does not have a right to any of the Issuer's securities issued as compensation for her service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options and any Common Stock acquired upon the exercise of Stock Options (i.e. no direct pecuniary interest)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C.\nBaker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to agreements between M. Cantey Boyd and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock acquired as a result of the exercise of the Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The acquisition of Stock Options reported on this form represents a single grant to M. Cantey Boyd of 25,000 Stock Options on Table II. This grant of 25,000 Stock Options for M. Cantey Boyd is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":25000,"derivative":{"exercise_price":0.79,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-036241","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000120919123036241/doc4.xml","form_type":"4"}}],"next_cursor":"2023-06-12T20:03:22.000000Z,1859442"}